Literature DB >> 29147862

Eosinophilia in a peritoneal dialysis patient: Answers.

Shimrit Tzvi-Behr1, Yaacov Frishberg2, Efrat Ben-Shalom2, Choni Rinat2, Rachel Becker-Cohen2.   

Abstract

Icodextrin is a starch-derived glucose polymer used in peritoneal dialysis dialysate to treat volume overload by increasing ultrafiltration in patients with end-stage renal disease. Reported adverse reactions to icodextrin are mild and rare and mainly consist of skin rash that resolves spontaneously after discontinuation of treatment. We describe a young patient with extreme eosinophilia that appeared with the use of icodextrin, disappeared after its discontinuation, and reappeared after a rechallenge with the drug. The eosinophilia was not associated with peritonitis, was asymptomatic, and fully resolved after discontinuation of the drug. Severe eosinophilia can potentially cause tissue damage in several organs, which would indicate that blood eosinophil count is recommended in routine complete blood counts while icodextrin peritoneal dialysis is being administered.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29147862     DOI: 10.1007/s00467-017-3847-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  Practical approach to the patient with hypereosinophilia.

Authors:  Florence Roufosse; Peter F Weller
Journal:  J Allergy Clin Immunol       Date:  2010-06-09       Impact factor: 10.793

2.  Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution.

Authors:  Robert MacGinley; Katrina Cooney; Geraldine Alexander; SueMien Cohen; David J A Goldsmith
Journal:  Am J Kidney Dis       Date:  2002-11       Impact factor: 8.860

3.  Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study.

Authors:  M K Chan; L Chow; S S Lam; B Jones
Journal:  Am J Kidney Dis       Date:  1988-02       Impact factor: 8.860

4.  Pruritic rash and eosinophilia in a patient receiving peritoneal dialysis.

Authors:  Umesh O Patel; Susan R Fox; James N Moy; Stephen M Korbet
Journal:  Semin Dial       Date:  2011 May-Jun       Impact factor: 3.455

5.  Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution.

Authors:  Leo Martis; Mehul Patel; Joe Giertych; Jim Mongoven; Michel Taminne; Michele A Perrier; Omar Mendoza; Niranjan Goud; Aidan Costigan; Nicole Denjoy; Christian Verger; William F Owen
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

6.  Blood eosinophilia in patients undergoing maintenance peritoneal dialysis.

Authors:  P K Chandran; H M Humayun; J T Daugirdas; Z M Nawab; V C Gandhi; T S Ing
Journal:  Arch Intern Med       Date:  1985-01

7.  Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial.

Authors:  Simon J Davies; Graham Woodrow; Kieron Donovan; Jörg Plum; Paul Williams; Ann Catherine Johansson; Hans-Peter Bosselmann; Olof Heimbürger; Ole Simonsen; Andrew Davenport; Anders Tranaeus; Jose C Divino Filho
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

8.  Use of new peritoneal dialysis solutions in children.

Authors:  A Canepa; E Verrina; F Perfumo
Journal:  Kidney Int Suppl       Date:  2008-04       Impact factor: 10.545

  8 in total
  1 in total

1.  Resolution of severe eosinophilic peritonitis in a patient on continuous ambulatory peritoneal dialysis by changing from Dianeal peritoneal dialysis solution to Stay-Safe Balance solution: a case report.

Authors:  Zi Chan; Yun Ho Hui; Sunny Sze Ho Wong
Journal:  BMC Nephrol       Date:  2022-04-18       Impact factor: 2.585

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.